List of Excipients in Branded Drug OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE 20/5/12.5 MG

Generic Drugs Containing OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE 20/5/12.5 MG

Company	Ingredient	NDC	Excipient
Torrent Pharmaceuticals Limited	olmesartan medoxomil, amlodipine and hydrochlorothiazide tablet 20/5/12.5 mg	13668-397	CROSCARMELLOSE SODIUM
Torrent Pharmaceuticals Limited	olmesartan medoxomil, amlodipine and hydrochlorothiazide tablet 20/5/12.5 mg	13668-397	FERRIC OXIDE RED
Torrent Pharmaceuticals Limited	olmesartan medoxomil, amlodipine and hydrochlorothiazide tablet 20/5/12.5 mg	13668-397	FERRIC OXIDE YELLOW
Torrent Pharmaceuticals Limited	olmesartan medoxomil, amlodipine and hydrochlorothiazide tablet 20/5/12.5 mg	13668-397	FERROSOFERRIC OXIDE

What are the Most Frequently-Used Excipients in OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE 20/5/12.5 MG?

# Of NDCs	Excipient
1	CROSCARMELLOSE SODIUM
1	FERRIC OXIDE RED
1	FERRIC OXIDE YELLOW
1	FERROSOFERRIC OXIDE

Excipient Strategy and Commercial Opportunities for Olmesartan Medoxomil, Amlodipine, and Hydrochlorothiazide 20/5/12.5 mg

Last updated: February 26, 2026

This analysis outlines excipient considerations and commercial landscape for a fixed-dose combination (FDC) of Olmesartan Medoxomil, Amlodipine, and Hydrochlorothiazide at the specified dosage.

What are the Key Excipient Strategy Elements?

1. Formulation Compatibility and Stability

• Active Ingredient Profile:
  Olmesartan Medoxomil is sensitive to moisture and prone to hydrolysis; Amlodipine and Hydrochlorothiazide have different stability profiles.
• Excipients:
  • Use moisture barriers such as desiccants or packaging with low moisture transmission rates.
  • Incorporate antioxidants like ascorbic acid to prevent degradation of sensitive active components.
  • Employ binders and fillers compatible with all three actives; microcrystalline cellulose and lactose are common choices.

2. Bioavailability and Release Profile

• Immediate vs. Controlled Release:

  • Most formulations opt for immediate release to ensure rapid therapeutic onset.
  • Controlled-release excipients are less relevant for this combination but may be considered to smooth plasma concentration peaks.

• Excipient Impact:

  • Excipients should not alter pharmacokinetics; compatibility studies are critical.
  • Disintegrants like croscarmellose sodium facilitate rapid dissolution of the combination tablet.

3. Patient Tolerability

• Sensitivities:
  • Excipients such as sodium lauryl sulfate should be minimized for sensitive populations.
  • Flavoring agents and coloring should follow regulatory safety standards for safety and tolerability.

4. Manufacturing and Scale-Up

• excipient selection impacts processability, compression force, and tablet weight uniformity.
• Compatibility with high-speed manufacturing lines reduces costs.

What Are the Commercial Opportunities?

1. Market Demand

• Hypertension Management:

  • The combination targets resistant hypertension or patients requiring multiple drugs.
  • The global antihypertensive market reached USD 25 billion in 2022 and is projected to grow annually at 3.8% through 2027 ([1]).

• Preference for Fixed-Dose Combinations:

  • Reduced pill burden increases adherence.
  • Regulatory agencies, including FDA and EMA, promote FDC approval to improve compliance.

2. Competitive Landscape

Product Name	Composition	Market Status	Key Competitors	Pricing Year (USD)	Market Share (Estimated)
Azor (Olmesartan/Amlodipine)	20/5 mg	Approved	Lotrel, Exforge	15-20 per month	10% of the FDC segment
Benicar-Hct (Olmesartan/HCTZ)	20/12.5 mg	Approved	Micardis-HCT	12-18 per month	5%
New FDC	20/5/12.5 mg	Under development	N/A	N/A	N/A

• Raising a new FDC offers patentability opportunities and narrower competition.

3. Regulatory Environment

• 21 countries and regions have approved Olmesartan-based FDCs.
• Regulatory pathways favor simplified filings; 505(b)(2) pathway can leverage existing data ([2]).

4. Commercial Strategies

• Patent Position: Confidentiality on formulation, device, or delivery method patents can extend exclusivity.
• Pricing Strategy: Target generic markets initially; premium pricing possible with improved tolerability or dosing convenience.
• Distribution Channels: Partner with large hospital chains and primary care networks.

5. Intellectual Property

• Patent filings focus on formulation, excipient combinations, and manufacturing processes.
• Patent protection duration extends up to 20 years from filing, with potential extensions.

What Are the Key Formulation and Commercial Risks?

• Excipient-related Risks:

  • Stability issues with moisture-sensitive components.
  • Consumer tolerability of excipients and excipient labeling.

• Market Entry Risks:

  • Brand competition from established products.
  • Patent challenges or generic competition upon patent expiry.

• Regulatory Hurdles:

  • Demonstrating bioequivalence and stability for FDC approval.

Key Takeaways

• Compound formulation requires careful selection of excipients to ensure stability, bioavailability, and patient tolerability.
• Market favors FDCs for hypertension due to improved adherence; regulatory pathways can streamline approval.
• Competitive advantage may come from patent-protected formulations, strategic pricing, and partnerships.

FAQs

1. How do excipients affect stability in this FDC?
Excipients influence moisture protection, prevent degradation, and facilitate tablet disintegration. Their compatibility with all active ingredients is essential to prevent chemical or physical instability.

2. What are common excipients for hypertension FDCs?
Microcrystalline cellulose (binder), croscarmellose sodium (disintegrant), magnesium stearate (lubricant), and low-moisture barrier packaging materials.

3. Can formulating this FDC extend patent life?
Yes, formulation patents, especially involving unique excipient combinations or delivery mechanisms, can provide patent protection beyond the active ingredients.

4. What regulatory pathways support this combination?
The 505(b)(2) pathway enables approval based on existing data, expedites registration, and is favored for reformulations or new combinations.

5. What are key commercial risks for launching this FDC?
High competition from branded and generic products, patent challenges, and formulary placement can impact market penetration and pricing.

---

References

[1] MarketsandMarkets. (2022). Hypertension drugs market.

[2] U.S. Food and Drug Administration. (2021). Fixed-dose combination drugs: Regulatory considerations.